Press Releases

Sign Up for News Alerts

2020

January 13, 2020
DNAtrix Appoints Jeff Knapp as Chief Executive Officer and to Board of Directors

2019

November 24, 2019
DNAtrix Presents Positive Results from the Phase 2 CAPTIVE/KEYNOTE-192 Study of DNX-2401 in Combination with Pembrolizumab for Glioblastoma at the 2019 SNO Annual Meeting

November 11, 2019
DNAtrix to Present Updated Results from the Phase 2 CAPTIVE / KEYNOTE-192 Study of DNX-2401 in Combination with Pembrolizumab for Glioblastoma at the 2019 SNO Annual Meeting

2018

November 26, 2018
DNAtrix’s Oncolytic Virus Expressing OX40 Ligand Treats First Patient in Recurrent Glioblastoma Clinical Trial

November 15, 2018
DNAtrix To Present Interim Phase 2 Results of DNX-2401 with Pembrolizumab for Glioblastoma

November 13, 2018
DNAtrix and Valo Therapeutics Enter into Strategic Partnership to Develop Peptide-Coated Oncolytic Viruses for Treating Cancer

November 7, 2018
Effectiveness of DNAtrix’s DNX-2440 Oncolytic Virus Expressing OX40L in Solid Tumors to be Presented at the 2018 Annual Meeting of the Society for Immunotherapy of Cancer

October 24, 2018
First Clinical Study Initiated for DNX-2440, DNAtrix's Next Generation Armed Oncolytic Virus

July 2, 2018
Treatment of Pediatric Brain Tumor, DIPG, with Oncolytic Adenovirus DNX-2401 to be Presented at the 2018 International Symposium for Pediatric Neuro-Oncology​ 

May 8, 2018
Successful Delivery of DNAtrix’s Oncolytic Virus DNX-2401 to Pediatric Brain Tumors​ 

April 12, 2018
Effectiveness of DNAtrix Oncolytic Virus DNX-2440 Armed with OX40L to be Presented at the 2018 American Association for Cancer Research Annual Meeting​ 

2017

December 5, 2017
DNAtrix Announces First Pediatric Patient Treated with Oncolytic Virus DNX-2401 

November 20, 2017
Mechanism of Action Studies for DNAtrix’s Oncolytic Virus DNX-2401 Presented at the 2017 Society for Neuro-Oncology Annual Meeting

November 13, 2017
DNAtrix Virus Expressing T-Cell Co-stimulator OX40L (CD252) Presented at the 2017 Society for Immunotherapy of Cancer Meeting

June 1, 2017
DNAtrix to Present Results of DNX-2401 for Recurrent Glioblastoma at the 2017 American Society of Clinical Oncology Annual Meeting

May 11, 2017
DNAtrix Oncolytic Myxoma Virus Eliminates Treatment-Resistant Cancer

April 24, 2017
Precision Intratumoral Delivery of DNX-2401 with the Alcyone MEMS Cannula

March 30, 2017
Antitumor Immunity Triggered by DNAtrix Armed Viruses to be Presented at the 2017 Annual Meeting of the American Association for Cancer Research

2016

November 17, 2016
DNAtrix to Present Clinical Data at the 21st Annual Meeting of the Society for Neuro-Oncology

November 8, 2016
DNAtrix Licenses Myxoma Virus for New Immunotherapy Platform

November 1, 2016
DNAtrix Announces First Patients Treated in Phase 2 Trial with DNX-2401 and KEYTRUDA

August 4, 2016
DNAtrix Awarded FDA Orphan Products Development Grant for DNX-2401

July 27, 2016
DNAtrix Receives European Medicines Agency PRIME Designation

July 21, 2016
DNAtrix Announces Successful Intratumoral Delivery of DNX-2401 via Alcyone’s MEMS Cannula for the Targeted Treatment of Recurrent Glioblastoma

February 9, 2016
DNAtrix’s Oncolytic Immunotherapy, DNX-2401, Awarded EU Orphan Medicine Designation for Treating Malignant Brain Tumors

 

Read older Press Releases